|
||||||||
![]() |
||||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|
Gateway® |
||||||||||||||||||||||||||||||||||||||||||||||||||||
The vector sequence has been compiled using the information from sequence databases, published literature, and other sources, together with partial sequences obtained by Evrogen. This vector has not been completely sequenced. |
|||||||||||||||||||||||||||||||||||||||||||||||||
![]() Download
|
| ||||||||||||||||||||||||||||||||||||||||||||||||
Location of features
attL1 site: 14-113
Kozak translation initiation site: 129-139
HyPer-AS: 136-1572
attL2 site: 1598-1697
Kanamycin resistance gene: 2922-3716
pUC origin of replication: 4301-4944
The HyPer-related materials (also referred to as "Products") are intended for research use only.
Invitrogen Gateway® Technology: please see Limited Use Label License No. 19: Gateway® Cloning Products.
|
Copyright 2002-2011 Evrogen. All rights reserved. Evrogen JSC, 16/10 Miklukho-Maklaya str., Moscow, Russia, Tel +7(495)988-4084, Fax +7(495)988-4085, e-mail:evrogen@evrogen.com |